CNAE treatment also led to a decrease in the amount of the proinflammatory cytokine interleukin-1-beta (IL-1β) and the osteoarthritis marker procollagen type II N-terminal propeptide, and to an increase in the osteoporosis markers procollagen type I N-terminal propeptide (PINP) and osteocalcin in the serum of the osteoporotic/osteoarthritic rats that were comparable to those that occurred when diclofenac treatment was administered. The gene discussed is IL1B; the disease is osteoporosis.